Login Register Cart 0
Current Drug Metabolism

Current Drug Metabolism

Editor-in-Chief

ISSN (Print): 1389-2002
ISSN (Online): 1875-5453

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Differential Pharmacokinetic Interplay of Atorvastatin on Lacosamide and Levetiracetam on Experimental Convulsions in Mice

Author(s): Jayaraman Rajangam*orcid of author, Arun Prasath Lakshmanan, Narahari N. Paleiorcid of author, Karthikeyan Elumalai, Muddukrishnaiah Kotakonda, R. Prakashorcid of author and P Latha

Volume 24, Issue 9, 2023

Published on: 25 October, 2023

Page: [645 - 655] Pages: 11

DOI: 10.2174/0113892002253895231020100743

Price: $65

Become a Editorial Board Member
Become a Reviewer
Become a Editor
Become a Section Editor

Abstract

Background: The beneficial effects of statins, other than their hypocholesterolemia role, have been well documented, however, their use as an adjuvant drug with other antiseizure drugs, in the treatment of epilepsy is poorly understood.

Objective: This study aimed to investigate the symbiotic effect of ATOR along with either lacosamide (LACO) or levetiracetam (LEVE) on experimentally induced epilepsy (Maximal electro-shock-MES or pentylenetetrazol- PTZ) in mice models.

Methods: Conventional elevated-maze (EPM) and rotarod methods were performed to observe the behavioral effects.

Results: In both the animal models, we found that co-administration of ATOR along with LACO showed a significant reduction in hind-limb extension (HLE) and clonic convulsion (CC) responses, respectively, but not in the ATOR+LEVE treated group. Intriguingly, comparable Straub tail response and myoclonic convulsion as the diazepam (DIA) group were observed only in the ATOR+LACO treated group. Moreover, a significant muscle-grip strength was observed in both groups. Also, pharmacokinetic analysis has indicated that the mean plasma concentration of ATOR peaked at 2nd hr in the presence of LACO but marginally peaked in the presence of LEVE. An Insilico study has revealed that ATOR has a higher binding affinity toward neuronal sodium channels.

Conclusion: This study has demonstrated that the plasma concentration of ATOR was potentiated in the presence of LACO, but not in the presence of LEVE and it has provided significant protection against both the electro and chemo-convulsive models in mice. This could be due to the symbiotic pharmacokinetic interplay of ATOR with LACO, and possibly, this interplay may interfere with sodium channel conductance.

Keywords: Atorvastatin, lacosamide, levetiracetam, epilepsy, pentylenetetrazol, pharmacokinetics.

« Previous Next »

Graphical Abstract

Graphical abstract illustrating key findings of the study

[1]
Wilson, P.W.F. Changing cholesterol levels and coronary heart disease risk. Circulation, 2016, 133(3), 239-241.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.115.020380] [PMID: 26659947]
[2]
Tobert, J.A. Lovastatin and beyond: The history of the HMG-CoA reductase inhibitors. Nat. Rev. Drug Discov., 2003, 2(7), 517-526.
[http://dx.doi.org/10.1038/nrd1112] [PMID: 12815379]
[3]
Bhat, A.; Dalvi, H.; Jain, H.; Rangaraj, N.; Singh, S.B.; Srivastava, S. Perspective insights of repurposing the pleiotropic efficacy of statins in neurodegenerative disorders: An expository appraisal. CRPHAR, 2021, 2, 100012.
[http://dx.doi.org/10.1016/j.crphar.2020.100012] [PMID: 34909647]
[4]
Tjardo, P.; Lyliana, G.N.; Maya, J.L.S.; Marc, M.B.; Peter, M.; Erna, V.H.; Selene, R.T.V.; Marieke, J.H.B.; Iris, E.C.S. Statins as an adjuvant therapy for psychotic disorders: Current evidence with a systematic overview of double-blind placebo controlled trials. J. Brain Dis., 2017, 1(1), 8.
[5]
Fracassi, A.; Marangoni, M.; Rosso, P.; Pallottini, V.; Fioramonti, M.; Siteni, S.; Segatto, M. Statins and the brain: More than lipid lowering agents? Curr. Neuropharmacol., 2018, 17(1), 59-83.
[http://dx.doi.org/10.2174/1570159X15666170703101816] [PMID: 28676012]
[6]
Tapia-Perez, J.H.; Sanchez-Aguilar, M.; Torres-Corzo, J.G.; Gordillo-Moscoso, A.; Martinez-Perez, P.; Madeville, P.; de la Cruz-Mendoza, E.; Chalita-Williams, J. Effect of rosuvastatin on amnesia and disorientation after traumatic brain injury (NCT003229758). J. Neurotrauma, 2008, 25(8), 1011-1017.
[http://dx.doi.org/10.1089/neu.2008.0554] [PMID: 18690806]
[7]
Stepień, K.; Tomaszewski, M.; Czuczwar, S.J. Neuroprotective properties of statins. Pharmacol. Rep., 2005, 57(5), 561-569.
[PMID: 16227638]
[8]
Shafaroodi, H.; Moezi, L.; Fakhrzad, A.; Hassanipour, M.; Rezayat, M.; Dehpour, A.R. The involvement of nitric oxide in the anti-seizure effect of acute atorvastatin treatment in mice. Neurol. Res., 2012, 34(9), 847-853.
[http://dx.doi.org/10.1179/1743132812Y.0000000080] [PMID: 22909758]
[9]
Candrilli, S.D.; Manjunath, R.; Davis, K.L.; Gidal, B.E. The association between antiepileptic drug and HMG-CoA reductase inhibitor co-medication and cholesterol management in patients with epilepsy. Epilepsy Res., 2010, 91(2-3), 260-266.
[http://dx.doi.org/10.1016/j.eplepsyres.2010.07.021] [PMID: 20801617]
[10]
Matsubara, S.; Tanaka, T.; Tomari, S.; Fukuma, K.; Ishiyama, H.; Abe, S.; Arimizu, T.; Yamaguchi, Y.; Ogata, S.; Nishimura, K.; Koga, M.; Ando, Y.; Toyoda, K.; Ihara, M. Statin treatment can reduce incidence of early seizure in acute ischemic stroke: A propensity score analysis. Sci. Rep., 2020, 10(1), 1968.
[http://dx.doi.org/10.1038/s41598-020-58652-w] [PMID: 32029801]
[11]
Verrotti, A.; Loiacono, G.; Olivieri, C.; Zulli, E.; Zaccara, G. Lacosamide in patients with pharmacoresistant epilepsy. Expert Opin. Pharmacother., 2012, 13(14), 2065-2072.
[http://dx.doi.org/10.1517/14656566.2012.713347] [PMID: 22873760]
[12]
Stafstrom, C.E. Epilepsy: A review of selected clinical syndromes and advances in basic science. J. Cereb. Blood Flow Metab., 2006, 26(8), 983-1004.
[http://dx.doi.org/10.1038/sj.jcbfm.9600265] [PMID: 16437061]
[13]
Wu, T.; Chuang, Y.C.; Huang, H.C.; Lim, S.N.; Hsieh, P.F.; Lee, W.T.; Cheng, M.Y.; Tsai, M.H.; Jou, S.B.; Chang, C.W.; Hsieh, H.Y.; Du, X.; Hellot, S.; McClung, C.; Hung, C. A prospective, multicenter, noninterventional study in Taiwan to evaluate the safety and tolerability of lacosamide as adjunctive therapy for epilepsy in clinical practice. Epilepsy Behav., 2020, 113, 107464.
[http://dx.doi.org/10.1016/j.yebeh.2020.107464] [PMID: 33152580]
[14]
Gurbani, S.; Chayasirisobhon, S.; Gurbani, A.; Tovar, S.; Pietzsch, E.; Spurgeon, B. Effectiveness at 24 months of single-source generic carbamazepine, lamotrigine, or levetiracetam in newly diagnosed focal epilepsy. Perm. J., 2021, 25(1), 1-3.
[http://dx.doi.org/10.7812/TPP/20.183] [PMID: 33635777]
[15]
Lin, H.W.; Ho, Y.F.; Lin, F.J. Statin use associated with lower risk of epilepsy after intracranial haemorrhage: A population-based cohort study. Br. J. Clin. Pharmacol., 2018, 84(9), 1970-1979.
[http://dx.doi.org/10.1111/bcp.13626] [PMID: 29714813]
[16]
Oliveira, C.V.; Grigoletto, J.; Canzian, J.M.; Duarte, M.M.M.F.; Duarte, T.; Furian, A.F.; Oliveira, M.S. Effect of atorvastatin on behavioral alterations and neuroinflammation during epileptogenesis. Epilepsy Behav., 2018, 78, 109-117.
[http://dx.doi.org/10.1016/j.yebeh.2017.10.021] [PMID: 29186698]
[17]
Scicchitano, F.; Constanti, A.; Citraro, R.; Sarro, G.; Russo, E. Statins and epilepsy: Preclinical studies, clinical trials and statin-anticonvulsant drug interactions. Curr. Drug Targets, 2015, 16(7), 747-756.
[http://dx.doi.org/10.2174/1389450116666150330114850] [PMID: 25901524]
[18]
Vossler, D.G.; Knake, S.; O’Brien, T.J.; Watanabe, M.; Brock, M.; Steiniger-Brach, B.; Williams, P.; Roebling, R. Efficacy and safety of adjunctive lacosamide in the treatment of primary generalised tonic-clonic seizures: a double-blind, randomised, placebo-controlled trial. J. Neurol. Neurosurg. Psychiatry, 2020, 91(10), 1067-1075.
[http://dx.doi.org/10.1136/jnnp-2020-323524] [PMID: 32817358]
[19]
Lattanzi, S.; Trinka, E.; Del Giovane, C.; Nardone, R.; Silvestrini, M.; Brigo, F. Antiepileptic drug monotherapy for epilepsy in the elderly: A systematic review and network meta-analysis. Epilepsia, 2019, 60(11), 2245-2254.
[http://dx.doi.org/10.1111/epi.16366] [PMID: 31608438]
[20]
Lynch, B.A.; Lambeng, N.; Nocka, K.; Kensel-Hammes, P.; Bajjalieh, S.M.; Matagne, A.; Fuks, B. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc. Natl. Acad. Sci., 2004, 101(26), 9861-9866.
[http://dx.doi.org/10.1073/pnas.0308208101] [PMID: 15210974]
[21]
Gupta, M. Levetiracetam-induced leukocytoclastic vasculitis. Indian J. Pharmacol., 2017, 49(1), 124-126.
[PMID: 28458437]
[22]
Arican, P.; Gencpinar, P.; Cavusoglu, D.; Olgac Dundar, N. Levetiracetam monotherapy for the treatment of infants with epilepsy. Seizure, 2018, 56, 73-77.
[http://dx.doi.org/10.1016/j.seizure.2018.02.006] [PMID: 29453114]
[23]
Harris, J.A.; Murphy, J.A. Lacosamide and Epilepsy. CNS Neurosci. Ther., 2011, 17(6), 678-682.
[http://dx.doi.org/10.1111/j.1755-5949.2010.00198.x] [PMID: 20950330]
[24]
Errington, A.C.; Stöhr, T.; Heers, C.; Lees, G. The investigational anticonvulsant lacosamide selectively enhances slow inactivation of voltage-gated sodium channels. Mol. Pharmacol., 2008, 73(1), 157-169.
[http://dx.doi.org/10.1124/mol.107.039867] [PMID: 17940193]
[25]
Beyreuther, B.K.; Freitag, J.; Heers, C.; Krebsfänger, N.; Scharfenecker, U.; Stöhr, T. Lacosamide: A review of preclinical properties. CNS Drug Rev., 2007, 13(1), 21-42.
[http://dx.doi.org/10.1111/j.1527-3458.2007.00001.x] [PMID: 17461888]
[26]
Wilson, S.M.; Khanna, R. Specific binding of lacosamide to collapsin response mediator protein 2 (CRMP2) and direct impairment of its canonical function: Implications for the therapeutic potential of lacosamide. Mol. Neurobiol., 2015, 51(2), 599-609.
[http://dx.doi.org/10.1007/s12035-014-8775-9] [PMID: 24944082]
[27]
Road, J.C. A novel simple test for tranquilizing activity: The chimny test. MedicinaExperimentalis, 1960, 3, 4.
[28]
Zhao, T.; Ding, Y.; Feng, X.; Zhou, C.; Lin, W. Effects of atorvastatin and aspirin on post-stroke epilepsy and usage of levetiracetam. Medicine, 2020, 99(50), e23577.
[http://dx.doi.org/10.1097/MD.0000000000023577] [PMID: 33327318]
[29]
Grados, S.D.; Gracia, G.A.; García, A.C. Transient sinus dysfunction secondary to lacosamide treatment. CorSalud., 2019, 11(2), 167-170.
[30]
Mintzer, S.; Skidmore, C.T.; Abidin, C.J.; Morales, M.C.; Chervoneva, I.; Capuzzi, D.M.; Sperling, M.R. Effects of antiepileptic drugs on lipids, homocysteine, and C-reactive protein. Ann. Neurol., 2009, 65(4), 448-456.
[http://dx.doi.org/10.1002/ana.21615] [PMID: 19296463]
[31]
Elliott, J.O.; Lu, B.; Shneker, B.; Charyton, C.; Layne Moore, J. Comorbidity, health screening, and quality of life among persons with a history of epilepsy. Epilepsy Behav., 2009, 14(1), 125-129.
[http://dx.doi.org/10.1016/j.yebeh.2008.10.013] [PMID: 18983943]
[32]
Miloushev, V.Z.; Levine, J.A.; Arbing, M.A.; Hunt, J.F.; Pitt, G.S.; Palmer, A.G. III Solution structure of the NaV1.2 C-terminal EF-hand domain. J. Biol. Chem., 2009, 284(10), 6446-6454.
[http://dx.doi.org/10.1074/jbc.M807401200] [PMID: 19129176]
[33]
Quintana-Pájaro, L.D.J.; Ramos-Villegas, Y.; Cortecero-Sabalza, E.; Joaquim, A.F.; Agrawal, A.; Narvaez-Rojas, A.R.; Moscote-Salazar, L.R. The effect of statins in epilepsy: A systematic review. J. Neurosci. Rural Pract., 2018, 9(4), 478-486.
[http://dx.doi.org/10.4103/jnrp.jnrp_110_18] [PMID: 30271037]
[34]
Trivedi, L.U.; Alvarez, C.A.; Mansi, I.A. Association of statin therapy with risk of epilepsy in 2 propensity score–matched cohorts. Ann. Pharmacother., 2018, 52(6), 546-553.
[http://dx.doi.org/10.1177/1060028018756650] [PMID: 29400081]
[35]
Permatananda, P.A.N.K.K. Adverse event of antiepileptic drugs: a cross sectional study. MATEC Web of Conferences., 2018, 197, p. 07004.
[36]
Zadeh, W.W.; Escartin, A.; Byrnes, W.; Tennigkeit, F.; Borghs, S.; Li, T.; Dedeken, P.; De Backer, M. Efficacy and safety of lacosamide as first add-on or later adjunctive treatment for uncontrolled partial-onset seizures: A multicentre open-label trial. Seizure, 2015, 31, 72-79.
[http://dx.doi.org/10.1016/j.seizure.2015.07.001] [PMID: 26362380]
[37]
Sirsi, D.; Safdieh, J.E. The safety of levetiracetam. Expert Opin. Drug Saf., 2007, 6(3), 241-250.
[http://dx.doi.org/10.1517/14740338.6.3.241] [PMID: 17480174]
[38]
White, H.S.; Johnson, M.; Wolf, H.H.; Kupferberg, H.J. The early identification of anticonvulsant activity: Role of the maximal electroshock and subcutaneous pentylenetetrazol seizure models. Ital. J. Neurol. Sci., 1995, 16(1-2), 73-77.
[http://dx.doi.org/10.1007/BF02229077] [PMID: 7642355]
[39]
Kandratavicius, L.; Balista, P.; Lopes-Aguiar, C.; Ruggiero, R.; Umeoka, E.; Garcia-Cairasco, N.; Bueno-Junior, L.; Leite, J. Animal models of epilepsy: Use and limitations. Neuropsychiatr. Dis. Treat., 2014, 10, 1693-1705.
[http://dx.doi.org/10.2147/NDT.S50371] [PMID: 25228809]
[40]
Löscher, W.; Schmidt, D. Which animal models should be used in the search for new antiepileptic drugs? A proposal based on experimental and clinical considerations. Epilepsy Res., 1988, 2(3), 145-181.
[http://dx.doi.org/10.1016/0920-1211(88)90054-X] [PMID: 3058469]
[41]
Swiader, M.; Łuszczki, J.; Wielosz, M.; Czuczwar, S.J. Influence of vigabatrin, a novel antiepileptic drug, on the anticonvulsant activity of conventional antiepileptics in pentetrazole-induced seizures in mice. Pol. J. Pharmacol., 2003, 55(3), 363-370.
[PMID: 14506315]
[42]
Klitgaard, H. Levetiracetam: The preclinical profile of a new class of antiepileptic drugs? Epilepsia, 2001, 42(S4), 13-18.
[http://dx.doi.org/10.1046/j.1528-1157.2001.00003.x] [PMID: 11564119]
[43]
Klein, P.; Friedman, A.; Hameed, M.Q.; Kaminski, R.M.; Bar-Klein, G.; Klitgaard, H.; Koepp, M.; Jozwiak, S.; Prince, D.A.; Rotenberg, A.; Twyman, R.; Vezzani, A.; Wong, M.; Löscher, W. Repurposed molecules for antiepileptogenesis: Missing an opportunity to prevent epilepsy? Epilepsia, 2020, 61(3), 359-386.
[http://dx.doi.org/10.1111/epi.16450] [PMID: 32196665]
[44]
Rajangam, J; Bhatt, S; Krishnan, N; Sammeta, M; Joshna, L Infl fluence of metformin on learning and memory in experimental amnesia model in mice. Ann Alzheimers Dement Care., 2020, 4(1), 005-009.
[45]
Rajangam, J.; Manogna, K.; Mounica, K.; Padma, C.; Swathi, A. Behavioural influence of Atorvastatin alone and in combination with antiepileptics against electroconvulsions in mice. Malays. J. Med. Bio. Res., 2017, 4(1), 63-70.
[http://dx.doi.org/10.18034/mjmbr.v4i1.426]
[46]
Sahu, D.R.; Chowdhury, B.; Sahoo, B.M. Anti-convulsant action and attenuation of oxidative stress by citrus limon peel extracts in PTZ and MES induced convulsion in Albino rats. Cent. Nerv. Syst. Agents Med. Chem., 2021, 20(3), 177-185.
[http://dx.doi.org/10.2174/1871524920999200831153214] [PMID: 32867662]
[47]
Jayaraman, R.; Lavanya, O. Effect of rosuvastatin on learning and memory in scopolamine induced amnesia in Mice. Trends in Medicine., 2018, 18, 1-4.
[48]
Sangshetti, J.N.; Aqeel, M.; Zaheer, Z.; Ahmed, R.Z.; Dehghan, M.H.G.; Gonjari, I. Development and validation of RP-HPLC method for determination of Atorvastatin calcium and Nicotinic acid in combined tablet dosage form. J. Saudi Chem. Soc., 2016, 20, S328-S333.
[http://dx.doi.org/10.1016/j.jscs.2012.12.005]
[49]
Siewert, S. Validation of a levofloxacin HPLC assay in plasma and dialysate for pharmacokinetic studies. J. Pharm. Biomed. Anal., 2006, 41(4), 1360-1362.
[http://dx.doi.org/10.1016/j.jpba.2006.02.010] [PMID: 16563690]
[50]
Franchi, F.; Marte, A.; Corradi, B.; Sterlini, B.; Alberini, G.; Romei, A.; De Fusco, A.; Vogel, A.; Maragliano, L.; Baldelli, P.; Corradi, A.; Valente, P.; Benfenati, F. The intramembrane COOH-terminal domain of PRRT2 regulates voltage-dependent Na+ channels. J. Biol. Chem., 2023, 299(5), 104632. Epub ahead of print
[http://dx.doi.org/10.1016/j.jbc.2023.104632] [PMID: 36958475]
[51]
Amanlou, A.; Nassireslami, E.; Dehpour, A.R.; Rashidian, A.; Chamanara, M. Beneficial effects of statins on seizures independent of their lipid-lowering effect: A narrative review. Iran. J. Med. Sci., 2023, 48(1), 13-25.
[http://dx.doi.org/10.30476/IJMS.2021.91645.2289] [PMID: 36688200]
[52]
Rizaldy, T.P.; Fransiscus, B.; Rosa De, L.R.S.; Andre, D.J. Antiepileptic drugs and quality of life in patients with epilepsy: A tertiary care hospitalbased study. Asian J. Pharm. Pharmacol., 2019, 5(2), 249-254.
[http://dx.doi.org/10.31024/ajpp.2019.5.2.5]
[53]
Biton, V; Gil-Nagel, A; Isojarvi, J; Doty, P; Hebert, D; Fountain, NB Safety and tolerability of lacosamide as adjunctive therapy for adults with partial-onset seizures: Analysis of data pooled from three randomized, double-blind, placebo-controlled clinical trials. Epilepsy Behav., 2015, 52(Pt A), 119-127.
[http://dx.doi.org/10.1016/j.yebeh.2015.09.006]
[54]
Briggs, D.E.; French, J.A. Levetiracetam safety profiles and tolerability in epilepsy patients. Expert Opin. Drug Saf., 2004, 3(5), 415-424.
[http://dx.doi.org/10.1517/14740338.3.5.415] [PMID: 15335297]
[55]
Giardina, W.J.; Gasior, M. Acute seizure tests in epilepsy research: Electroshock- and chemical-induced convulsions in the mouse; Curr Protoc Pharmaco, 2009.
[http://dx.doi.org/10.1002/0471141755.ph0522s45]
[56]
Becker, A.J. Review: Animal models of acquired epilepsy: Insights into mechanisms of human epileptogenesis. Neuropathol. Appl. Neurobiol., 2018, 44(1), 112-129.
[http://dx.doi.org/10.1111/nan.12451] [PMID: 29130506]
[57]
Rogawski, M.A. Molecular targets versus models for new antiepileptic drug discovery. Epilepsy Res., 2006, 68(1), 22-28.
[http://dx.doi.org/10.1016/j.eplepsyres.2005.09.012] [PMID: 16377151]
[58]
Klitgaard, H.; Matagne, A.; Gobert, J.; Wülfert, E. Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy. Eur. J. Pharmacol., 1998, 353(2-3), 191-206.
[http://dx.doi.org/10.1016/S0014-2999(98)00410-5] [PMID: 9726649]
[59]
Matagne, A.; Margineanu, D-G.; Kenda, B.; Michel, P.; Klitgaard, H. Anti-convulsive and anti-epileptic properties of brivaracetam (ucb 34714), a high-affinity ligand for the synaptic vesicle protein, SV2A. Br. J. Pharmacol., 2008, 154(8), 1662-1671.
[http://dx.doi.org/10.1038/bjp.2008.198] [PMID: 18500360]
[60]
Jayaraman, R.; Manisenthil, K.T.; Anitha, T.; Joshi, V.D.; Palei, N.N.; Gajera, K.; Ladani, K. Influence of etoricoxib on anticonvulsant activity of phenytoin and diazepam in experimental seizure models in mice. J. Pharm. Pharmacol., 2010, 62(5), 610-614.
[http://dx.doi.org/10.1211/jpp.62.05.0008] [PMID: 20609063]
[61]
Kaminski, R.M.; Matagne, A.; Patsalos, P.N.; Klitgaard, H. Benefit of combination therapy in epilepsy: A review of the preclinical evidence with levetiracetam. Epilepsia, 2009, 50(3), 387-397.
[http://dx.doi.org/10.1111/j.1528-1167.2008.01713.x] [PMID: 18627416]
[62]
Hardman, J.GLL.; Goodman, A. Drugs effective in the therapy of the epilepsies; McGraw-Hill: New York, USA, 2010, p. 27.
[63]
Yaari, Y.; Selzer, M.E.; Pincus, J.H. Phenytoin: Mechanisms of its anticonvulsant action. Ann. Neurol., 1986, 20(2), 171-184.
[http://dx.doi.org/10.1002/ana.410200202] [PMID: 2428283]
[64]
Cook, A.M.; Bensalem-Owen, M.K. Mechanisms of action of antiepileptic drugs. Therapy, 2011, 8(3), 307-313.
[http://dx.doi.org/10.2217/thy.11.19]
[65]
W S. A sensitive biological response to morphine. Dtsch. Med. Wochenschr., 1911, 37.
[66]
Bilbey, D.L.J.; Salem, H.; Grossman, M.H. The anatomical basis of the straub phenomenon. Br. J. Pharmacol. Chemother., 1960, 15(4), 540-543.
[http://dx.doi.org/10.1111/j.1476-5381.1960.tb00277.x] [PMID: 19108140]
[67]
Orrin Devinsky, J.I.S. Myoclonic Seizures; , 2014. Available from:https://www.epilepsy.com/learn/types-seizures/myoclonic-seizures
[68]
Ruth, A. Medications, Herbal Preparations, and Natural Products in Breast Milk; Ruth, A.; Lawrence, RML, Eds.; W.B. Saunders , 2011; p. 43.
[69]
Lesser, R.P.; Lüders, H.; Wyllie, E.; Dinner, D.S.; Iii, H.H.M. Mental deterioration in epilepsy. Epilepsia, 1986, 27(S2), S105-S123.
[http://dx.doi.org/10.1111/j.1528-1157.1986.tb05735.x] [PMID: 3720708]
[70]
Moezi, L.; Shafaroodi, H.; Hassanipour, M.; Fakhrzad, A.; Hassanpour, S.; Dehpour, A.R. Chronic administration of atorvastatin induced anti-convulsant effects in mice: The role of nitric oxide. Epilepsy Behav., 2012, 23(4), 399-404.
[http://dx.doi.org/10.1016/j.yebeh.2012.02.001] [PMID: 22405864]
[71]
Hogg, S. A review of the validity and variability of the Elevated Plus-Maze as an animal model of anxiety. Pharmacol. Biochem. Behav., 1996, 54(1), 21-30.
[http://dx.doi.org/10.1016/0091-3057(95)02126-4] [PMID: 8728535]
[72]
Itoh, J.; Nabeshima, T.; Kameyama, T. Utility of an elevated plus-maze for the evaluation of memory in mice: effects of nootropics, scopolamine and electroconvulsive shock. Psychopharmacology, 1990, 101(1), 27-33.
[http://dx.doi.org/10.1007/BF02253713] [PMID: 2343073]
[73]
Deacon, R.M. Measuring motor coordination in mice. J. Vis. Exp., 2013, (75), e2609.
[PMID: 23748408]
[74]
Sohn, Y.H.; Jung, H.Y.; Kaelin-Lang, A.; Hallett, M. Effect of levetiracetam on rapid motor learning in humans. Arch. Neurol., 2002, 59(12), 1909-1912.
[http://dx.doi.org/10.1001/archneur.59.12.1909] [PMID: 12470179]
[75]
Lang, N.; Rothkegel, H.; Peckolt, H.; Deuschl, G. Effects of lacosamide and carbamazepine on human motor cortex excitability: A double-blind, placebo-controlled transcranial magnetic stimulation study. Seizure, 2013, 22(9), 726-730.
[http://dx.doi.org/10.1016/j.seizure.2013.05.010] [PMID: 23778157]
[76]
Nayak, V.A.S.; Poornima, B.M.; Sharma, R.; Garg, A.; Shetty, M.; Kamath, S.; Hegde, M.; Koshy, S.S. Effect of chronic administration of atorvastatin, simvastatin and lovastatin on animal models of epilepsy. Int. J. Curr. Res. Rev., 2013, 05(19), 5.
[77]
Ashwini, P.R.M.S. Potential anti-seizure activity of atorvastatin in rat models of seizure. Int. J. Basic Clin. Pharmacol., 2017, 6(1), 4.
[78]
Mohammad, J.K.; Nader, T.; Samaneh, N. Anticonvulsant activity of atorvastatin against seizure induced by pentylenetetrazole and maximal electroshock in mice trends in pharmaceutical sciences. Trends Pharmacol. Sci., 2015, 1(1), 44-47.
[79]
Mazzu, A.; Lasseter, K.C.; Shamblen, E.C.; Agarwal, V.; Lettieri, J.; Sundaresen, P. Itraconazole alters the pharmacokinetics of atorvastatin to a greater extent than either cerivastatin or pravastatin. Clin. Pharmacol. Ther., 2000, 68(4), 391-400.
[http://dx.doi.org/10.1067/mcp.2000.110537] [PMID: 11061579]
[80]
Backman, J.; Luurila, H.; Neuvonen, M.; Neuvonen, P. Rifampin markedly decreases and gemfibrozil increases the plasma concentrations of atorvastatin and its metabolites. Clin. Pharmacol. Ther., 2005, 78(2), 154-167.
[http://dx.doi.org/10.1016/j.clpt.2005.04.007] [PMID: 16084850]
[81]
Paciullo, F.; Costa, C.; Gresele, P. Rivaroxaban plasma levels and levetiracetam: A case report. Ann. Intern. Med., 2020, 173(1), 71-72.
[http://dx.doi.org/10.7326/L19-0712] [PMID: 32283551]
[82]
Cawello, W; Surmann, E; Waitzinger, J. Lacosamide has no effect on the enzymatic activity of CYP3A4 (P01.076). Neurology., 2012, 78(S1), P01.076.

Rights & Permissions Print Cite
Article Metrics
Pdf icon 49
Html icon 2
Find your institution